Covestor’s Celldex Therapeutics CLDX Stock Holding History
Bought
Maintained
Sold
Other funds holding CLDX
Covestor's CLDX Position: Q3 2026 in Review
Covestor reduced its Celldex Therapeutics (CLDX) stake by 39% in Q3 2026, selling an estimated $268 and leaving 11 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2421.
Covestor first reported a position in CLDX in Q4 2021 and has held it in 20 quarters since. The position peaked at $1K in Q2 2026. 166 funds tracked by Wall St. Rank hold CLDX as of Q3 2026.
- Covestor held 11 shares of Celldex Therapeutics worth $0 as of Q3 2026.
- Covestor sold 7 Celldex Therapeutics shares in Q3 2026, an estimated $268.
- Celldex Therapeutics made up ﹤0.01% of Covestor's portfolio in Q3 2026, its #2421 holding.
- Covestor first reported a position in Celldex Therapeutics in Q4 2021 and has held it in 20 quarters since.
- Covestor's Celldex Therapeutics position peaked at $1K in Q2 2026.
- 166 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2026.
Based on Covestor's 13F filing for Q3 2026, filed 30 Oct 2026.